EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†

A. Horwich; M. Babjuk; J. Bellmunt; H. M. Bruins; T. M.De Reijke; M. De Santis; S. Gillessen; N. James; S. Maclennan; J. Palou; T. Powles; M. J. Ribal; S. F. Shariat; T. Van Der Kwast; E. Xylinas; N. Agarwal; T. Arends; A. Bamias; A. Birtle; P. C. Black; B. H. Bochner; M. Bolla; J. L. Boormans; A. Bossi; A. Briganti; I. Brummelhuis; M. Burger; D. Castellano; R. Cathomas; A. Chiti; A. Choudhury; E. Compérat; S. Crabb; S. Culine; B. De Bari; W. De Blok; P. J.L. De Visschere; K. Decaestecker; K. Dimitropoulos; J. L. Dominguez-Escrig; S. Fanti; V. Fonteyne; M. Frydenberg; J. J. Futterer; G. Gakis; B. Geavlete; P. Gontero; B. Grubmüller; S. Hafeez; D. E. Hansel; A. Hartmann; D. Hayne; A. M. Henry; V. Hernandez; H. Herr; K. Herrmann; P. Hoskin; J. Huguet; B. A. Jereczek-Fossa; R. Jones; A. M. Kamat; V. Khoo; A. E. Kiltie; S. Krege; S. Ladoire; P. C. Lara; A. Leliveld; E. Linares-Espinós; V. Løgager; A. Lorch; Y. Loriot; R. Meijer; M. Carmen Mir; M. Moschini; H. Mostafid; A. C. Müller; C. R. Müller; J. N'Dow; A. Necchi; Y. Neuzillet; J. R. Oddens; J. Oldenburg; S. Osanto; W. J.G. Oyen; L. Pacheco-Figueiredo; H. Pappot; M. I. Patel; B. R. Pieters; K. Plass; M. Remzi; M. Retz; J. Richenberg; M. Rink; F. Roghmann; J. E. Rosenberg; M. Rouprêt; O. Rouvière; C. Salembier; A. Salminen; P. Sargos; S. Sengupta; A. Sherif; R. J. Smeenk; A. Smits; A. Stenzl; G. N. Thalmann; B. Tombal; B. Turkbey; S. Vahr Lauridsen; R. Valdagni; A. G. Van Der Heijden; H. Van Poppel; M. D. Vartolomei; E. Veskimäe; A. Vilaseca; F. A.Vives Rivera; T. Wiegel; P. Wiklund; A. Williams; R. Zigeuner; J. A. Witjes

doi:10.1093/annonc/mdz296

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†

A. Horwich, M. Babjuk, J. Bellmunt, H. M. Bruins, T. M.De Reijke, M. De Santis, S. Gillessen, N. James, S. Maclennan, J. Palou, T. Powles, M. J. Ribal, S. F. Shariat, T. Van Der Kwast, E. Xylinas, N. Agarwal, T. Arends, A. Bamias, A. Birtle, P. C. BlackB. H. Bochner, M. Bolla, J. L. Boormans, A. Bossi, A. Briganti, I. Brummelhuis, M. Burger, D. Castellano, R. Cathomas, A. Chiti, A. Choudhury, E. Compérat, S. Crabb, S. Culine, B. De Bari, W. De Blok, P. J.L. De Visschere, K. Decaestecker, K. Dimitropoulos, J. L. Dominguez-Escrig, S. Fanti, V. Fonteyne, M. Frydenberg, J. J. Futterer, G. Gakis, B. Geavlete, P. Gontero, B. Grubmüller, S. Hafeez, D. E. Hansel, A. Hartmann, D. Hayne, A. M. Henry, V. Hernandez, H. Herr, K. Herrmann, P. Hoskin, J. Huguet, B. A. Jereczek-Fossa, R. Jones, A. M. Kamat, V. Khoo, A. E. Kiltie, S. Krege, S. Ladoire, P. C. Lara, A. Leliveld, E. Linares-Espinós, V. Løgager, A. Lorch, Y. Loriot, R. Meijer, M. Carmen Mir, M. Moschini, H. Mostafid, A. C. Müller, C. R. Müller, J. N'Dow, A. Necchi, Y. Neuzillet, J. R. Oddens, J. Oldenburg, S. Osanto, W. J.G. Oyen, L. Pacheco-Figueiredo, H. Pappot, M. I. Patel, B. R. Pieters, K. Plass, M. Remzi, M. Retz, J. Richenberg, M. Rink, F. Roghmann, J. E. Rosenberg, M. Rouprêt, O. Rouvière, C. Salembier, A. Salminen, P. Sargos, S. Sengupta, A. Sherif, R. J. Smeenk, A. Smits, A. Stenzl, G. N. Thalmann, B. Tombal, B. Turkbey, S. Vahr Lauridsen, R. Valdagni, A. G. Van Der Heijden, H. Van Poppel, M. D. Vartolomei, E. Veskimäe, A. Vilaseca, F. A.Vives Rivera, T. Wiegel, P. Wiklund, A. Williams, R. Zigeuner, J. A. Witjes

Research output: Contribution to journal › Article › Other › peer-review

52 Citations (Scopus)

Abstract

BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference. SETTING: Online Delphi survey and consensus conference. PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease. CONCLUSIONS: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach.

Original language	English
Pages (from-to)	1697-1727
Number of pages	31
Journal	Annals of Oncology
Volume	30
Issue number	11
DOIs	https://doi.org/10.1093/annonc/mdz296
Publication status	Published - 1 Nov 2019

Keywords

bladder cancer
consensus
Delphi
diagnosis
follow-up
treatment

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdz296

Cite this

Horwich, A., Babjuk, M., Bellmunt, J., Bruins, H. M., Reijke, T. M. D., Santis, M. D., Gillessen, S., James, N., Maclennan, S., Palou, J., Powles, T., Ribal, M. J., Shariat, S. F., Kwast, T. V. D., Xylinas, E., Agarwal, N., Arends, T., Bamias, A., Birtle, A., ... Witjes, J. A. (2019). EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. Annals of Oncology, 30(11), 1697-1727. https://doi.org/10.1093/annonc/mdz296

@article{1049da894dc8468db7129f0b825a1d23,

title = "EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†",

abstract = "BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference. SETTING: Online Delphi survey and consensus conference. PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease. CONCLUSIONS: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach.",

keywords = "bladder cancer, consensus, Delphi, diagnosis, follow-up, treatment",

author = "A. Horwich and M. Babjuk and J. Bellmunt and Bruins, {H. M.} and Reijke, {T. M.De} and Santis, {M. De} and S. Gillessen and N. James and S. Maclennan and J. Palou and T. Powles and Ribal, {M. J.} and Shariat, {S. F.} and Kwast, {T. Van Der} and E. Xylinas and N. Agarwal and T. Arends and A. Bamias and A. Birtle and Black, {P. C.} and Bochner, {B. H.} and M. Bolla and Boormans, {J. L.} and A. Bossi and A. Briganti and I. Brummelhuis and M. Burger and D. Castellano and R. Cathomas and A. Chiti and A. Choudhury and E. Comp{\'e}rat and S. Crabb and S. Culine and Bari, {B. De} and Blok, {W. De} and {De Visschere}, {P. J.L.} and K. Decaestecker and K. Dimitropoulos and Dominguez-Escrig, {J. L.} and S. Fanti and V. Fonteyne and M. Frydenberg and Futterer, {J. J.} and G. Gakis and B. Geavlete and P. Gontero and B. Grubm{\"u}ller and S. Hafeez and Hansel, {D. E.} and A. Hartmann and D. Hayne and Henry, {A. M.} and V. Hernandez and H. Herr and K. Herrmann and P. Hoskin and J. Huguet and Jereczek-Fossa, {B. A.} and R. Jones and Kamat, {A. M.} and V. Khoo and Kiltie, {A. E.} and S. Krege and S. Ladoire and Lara, {P. C.} and A. Leliveld and E. Linares-Espin{\'o}s and V. L{\o}gager and A. Lorch and Y. Loriot and R. Meijer and Mir, {M. Carmen} and M. Moschini and H. Mostafid and M{\"u}ller, {A. C.} and M{\"u}ller, {C. R.} and J. N'Dow and A. Necchi and Y. Neuzillet and Oddens, {J. R.} and J. Oldenburg and S. Osanto and Oyen, {W. J.G.} and L. Pacheco-Figueiredo and H. Pappot and Patel, {M. I.} and Pieters, {B. R.} and K. Plass and M. Remzi and M. Retz and J. Richenberg and M. Rink and F. Roghmann and Rosenberg, {J. E.} and M. Roupr{\^e}t and O. Rouvi{\`e}re and C. Salembier and A. Salminen and P. Sargos and S. Sengupta and A. Sherif and Smeenk, {R. J.} and A. Smits and A. Stenzl and Thalmann, {G. N.} and B. Tombal and B. Turkbey and Lauridsen, {S. Vahr} and R. Valdagni and {Van Der Heijden}, {A. G.} and {Van Poppel}, H. and Vartolomei, {M. D.} and E. Veskim{\"a}e and A. Vilaseca and Rivera, {F. A.Vives} and T. Wiegel and P. Wiklund and A. Williams and R. Zigeuner and Witjes, {J. A.}",

year = "2019",

month = nov,

day = "1",

doi = "10.1093/annonc/mdz296",

language = "English",

volume = "30",

pages = "1697--1727",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier BV",

number = "11",

}

Horwich, A, Babjuk, M, Bellmunt, J, Bruins, HM, Reijke, TMD, Santis, MD, Gillessen, S, James, N, Maclennan, S, Palou, J, Powles, T, Ribal, MJ, Shariat, SF, Kwast, TVD, Xylinas, E, Agarwal, N, Arends, T, Bamias, A, Birtle, A, Black, PC, Bochner, BH, Bolla, M, Boormans, JL, Bossi, A, Briganti, A, Brummelhuis, I, Burger, M, Castellano, D, Cathomas, R, Chiti, A, Choudhury, A, Compérat, E, Crabb, S, Culine, S, Bari, BD, Blok, WD, De Visschere, PJL, Decaestecker, K, Dimitropoulos, K, Dominguez-Escrig, JL, Fanti, S, Fonteyne, V, Frydenberg, M, Futterer, JJ, Gakis, G, Geavlete, B, Gontero, P, Grubmüller, B, Hafeez, S, Hansel, DE, Hartmann, A, Hayne, D, Henry, AM, Hernandez, V, Herr, H, Herrmann, K, Hoskin, P, Huguet, J, Jereczek-Fossa, BA, Jones, R, Kamat, AM, Khoo, V, Kiltie, AE, Krege, S, Ladoire, S, Lara, PC, Leliveld, A, Linares-Espinós, E, Løgager, V, Lorch, A, Loriot, Y, Meijer, R, Mir, MC, Moschini, M, Mostafid, H, Müller, AC, Müller, CR, N'Dow, J, Necchi, A, Neuzillet, Y, Oddens, JR, Oldenburg, J, Osanto, S, Oyen, WJG, Pacheco-Figueiredo, L, Pappot, H, Patel, MI, Pieters, BR, Plass, K, Remzi, M, Retz, M, Richenberg, J, Rink, M, Roghmann, F, Rosenberg, JE, Rouprêt, M, Rouvière, O, Salembier, C, Salminen, A, Sargos, P, Sengupta, S, Sherif, A, Smeenk, RJ, Smits, A, Stenzl, A, Thalmann, GN, Tombal, B, Turkbey, B, Lauridsen, SV, Valdagni, R, Van Der Heijden, AG, Van Poppel, H, Vartolomei, MD, Veskimäe, E, Vilaseca, A, Rivera, FAV, Wiegel, T, Wiklund, P, Williams, A, Zigeuner, R & Witjes, JA 2019, 'EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†', Annals of Oncology, vol. 30, no. 11, pp. 1697-1727. https://doi.org/10.1093/annonc/mdz296

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort : under the auspices of the EAU and ESMO Guidelines Committees†. / Horwich, A.; Babjuk, M.; Bellmunt, J. et al.

In: Annals of Oncology, Vol. 30, No. 11, 01.11.2019, p. 1697-1727.

Research output: Contribution to journal › Article › Other › peer-review

TY - JOUR

T1 - EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort

T2 - under the auspices of the EAU and ESMO Guidelines Committees†

AU - Horwich, A.

AU - Babjuk, M.

AU - Bellmunt, J.

AU - Bruins, H. M.

AU - Reijke, T. M.De

AU - Santis, M. De

AU - Gillessen, S.

AU - James, N.

AU - Maclennan, S.

AU - Palou, J.

AU - Powles, T.

AU - Ribal, M. J.

AU - Shariat, S. F.

AU - Kwast, T. Van Der

AU - Xylinas, E.

AU - Agarwal, N.

AU - Arends, T.

AU - Bamias, A.

AU - Birtle, A.

AU - Black, P. C.

AU - Bochner, B. H.

AU - Bolla, M.

AU - Boormans, J. L.

AU - Bossi, A.

AU - Briganti, A.

AU - Brummelhuis, I.

AU - Burger, M.

AU - Castellano, D.

AU - Cathomas, R.

AU - Chiti, A.

AU - Choudhury, A.

AU - Compérat, E.

AU - Crabb, S.

AU - Culine, S.

AU - Bari, B. De

AU - Blok, W. De

AU - De Visschere, P. J.L.

AU - Decaestecker, K.

AU - Dimitropoulos, K.

AU - Dominguez-Escrig, J. L.

AU - Fanti, S.

AU - Fonteyne, V.

AU - Frydenberg, M.

AU - Futterer, J. J.

AU - Gakis, G.

AU - Geavlete, B.

AU - Gontero, P.

AU - Grubmüller, B.

AU - Hafeez, S.

AU - Hansel, D. E.

AU - Hartmann, A.

AU - Hayne, D.

AU - Henry, A. M.

AU - Hernandez, V.

AU - Herr, H.

AU - Herrmann, K.

AU - Hoskin, P.

AU - Huguet, J.

AU - Jereczek-Fossa, B. A.

AU - Jones, R.

AU - Kamat, A. M.

AU - Khoo, V.

AU - Kiltie, A. E.

AU - Krege, S.

AU - Ladoire, S.

AU - Lara, P. C.

AU - Leliveld, A.

AU - Linares-Espinós, E.

AU - Løgager, V.

AU - Lorch, A.

AU - Loriot, Y.

AU - Meijer, R.

AU - Mir, M. Carmen

AU - Moschini, M.

AU - Mostafid, H.

AU - Müller, A. C.

AU - Müller, C. R.

AU - N'Dow, J.

AU - Necchi, A.

AU - Neuzillet, Y.

AU - Oddens, J. R.

AU - Oldenburg, J.

AU - Osanto, S.

AU - Oyen, W. J.G.

AU - Pacheco-Figueiredo, L.

AU - Pappot, H.

AU - Patel, M. I.

AU - Pieters, B. R.

AU - Plass, K.

AU - Remzi, M.

AU - Retz, M.

AU - Richenberg, J.

AU - Rink, M.

AU - Roghmann, F.

AU - Rosenberg, J. E.

AU - Rouprêt, M.

AU - Rouvière, O.

AU - Salembier, C.

AU - Salminen, A.

AU - Sargos, P.

AU - Sengupta, S.

AU - Sherif, A.

AU - Smeenk, R. J.

AU - Smits, A.

AU - Stenzl, A.

AU - Thalmann, G. N.

AU - Tombal, B.

AU - Turkbey, B.

AU - Lauridsen, S. Vahr

AU - Valdagni, R.

AU - Van Der Heijden, A. G.

AU - Van Poppel, H.

AU - Vartolomei, M. D.

AU - Veskimäe, E.

AU - Vilaseca, A.

AU - Rivera, F. A.Vives

AU - Wiegel, T.

AU - Wiklund, P.

AU - Williams, A.

AU - Zigeuner, R.

AU - Witjes, J. A.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference. SETTING: Online Delphi survey and consensus conference. PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease. CONCLUSIONS: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach.

AB - BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference. SETTING: Online Delphi survey and consensus conference. PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease. CONCLUSIONS: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach.

KW - bladder cancer

KW - consensus

KW - Delphi

KW - diagnosis

KW - follow-up

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85077175940&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz296

DO - 10.1093/annonc/mdz296

M3 - Article

C2 - 31740927

VL - 30

SP - 1697

EP - 1727

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 11

ER -

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort^†[Formula presented]: Under the Auspices of the EAU-ESMO Guidelines Committees

Cite this

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Research output

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†[Formula presented]: Under the Auspices of the EAU-ESMO Guidelines Committees

Cite this

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort^†[Formula presented]: Under the Auspices of the EAU-ESMO Guidelines Committees